
Lincoln Pharma Q2 FY27: PAT up 2% YoY as margins compress, revenue +17%
Lincoln Pharmaceuticals reported consolidated (and effectively identical standalone) revenue from operations of ₹191.35 Cr for Q2 FY27, up 17.1% YoY from ₹163.36 Cr and up 7.9% QoQ from ₹177.28 Cr in Q1 FY27. Profit did not keep pace: consolidated PAT was ₹20.43 Cr, up just 2.2% YoY from ₹19.98 Cr, and down 43.6% QoQ from ₹36.23 Cr in Q1 FY27. EPS was ₹10.20 against ₹9.98 a year earlier. Neither period carried exceptional items, so this is a clean like-for-like reported comparison, not a one-off distortion. The gap between revenue and profit growth shows up in margins. Operating margin (PBT + finance cost + depreciation, less other income, over revenue from operations) fell to roughly 12.4% from about 15.5% both a year ago and last quarter, while net profit margin on total income slipped to 10.2% from 17.98% in Q1 FY27 and 11.71% in Q2 FY26. Total expenses rose faster than income this quarter, with cost of materials consumed the single largest line at ₹77.47 Cr. Tax of ₹8.59 Cr included a ₹1.74 Cr short provision for prior years, a modest additional drag on reported PAT but not the main story — the main story is expense growth outrunning revenue growth. No street estimates could be found for this print: a pre-result preview explicitly noted that no analyst consensus for Lincoln Pharma's Q2 FY27 was in the public domain, so vsStreet is unknown rather than inferred. The company also has no formal prior guidance on record for this specific quarter, so the print cannot be graded against a stated target; alongside results it reiterated a three-year ambition of ₹1,000 Cr revenue at 15-18% annual growth led by cardiac, diabetic, dermatology and ENT segments — a forward target, not a backward-looking guidance score. During the quarter the company launched four new domestic divisions and commissioned an API facility at its Khatraj plant, closed its trading window ahead of results, saw its senior QA General Manager resign (with a replacement appointed the same week), held its 32nd AGM approving an FY26 final dividend of ₹1.80/share, and saw FII holding rise to 4.55% as of September 30, 2026 — none of which directly explains the margin compression, which traces to the expense-side numbers above. Management's press release framed the quarter as "another strong quarter, reflecting our focus on sustainable growth," a framing that holds on the topline (+17.75% YoY per the release's total income figure) but sits uneasily against 2% YoY PAT growth and sequential margin compression visible in the filed statements; the release's own EBITDA growth figure of 1.71% YoY (₹33.22 Cr vs ₹32.66 Cr) is consistent with the margin pressure flagged here, even though the accompanying commentary emphasizes growth over margin.
Key Highlights
- Consolidated PAT ₹20.43 Cr, up just 2.2% YoY (₹19.98 Cr in Q2 FY26) despite 17.1% YoY revenue growth — profit growth lagged sharply behind the topline.
- Revenue from operations ₹191.35 Cr, up 17.1% YoY and 7.9% QoQ (₹177.28 Cr in Q1 FY27).
- QoQ profit fell 43.6%, from ₹36.23 Cr in Q1 FY27 to ₹20.43 Cr — a sharp sequential slowdown after a strong first quarter.
- Net profit margin compressed to 10.17% of total income, down from 17.98% in Q1 FY27 and 11.71% in Q2 FY26; operating margin fell to ~12.4% from ~15.5% in both comparison periods.
- EPS ₹10.20 (basic and diluted, not annualised) vs ₹9.98 a year ago, up 2.2%; no exceptional items in either period.
- Management reiterated a target of ₹1,000 Cr revenue over the next three years at 15-18% annual growth, led by cardiac, diabetic, dermatology and ENT segments; 32nd AGM approved an FY26 final dividend of ₹1.80/share (18%).
- Company remains net-debt free; FII holding rose to 4.55% as of September 30, 2026.
Price Impact
More from LINCOLN